TY - JOUR
T1 - Clinical utility of the liposteroid therapy
T2 - Potential effects on the macrophage activation
AU - Wakiguchi, Hiroyuki
AU - Ohga, Shouichi
N1 - Publisher Copyright:
© 2016 The Japan Society for Clinical Immunology.
PY - 2016
Y1 - 2016
N2 - Liposteroid, a lipid emulsion containing dexamethasone, was developed in Japan. This drug is effective against rheumatoid arthritis, and has fewer side effects than dexamethasone. Moreover, at high dosage, liposteroid has been effectively used for the treatment of macrophage activation syndrome, because the lipid emulsions are easily taken up by phagocytes, and are retained in macrophages. Its anti-inflammatory effect was found to be 2-5 times higher than that of dexamethasone in arthritis and granuloma rat models. Japanese researchers have reported the clinical efficacy and utility of liposteroid in the treatment of diseases with macrophage activation. These include hemophagocytic lymphohistiocytosis, graft-versus-host disease, and pulmonary hemosiderosis. Here, we describe the clinical effects of liposteroid on macrophage activation syndrome and the hypothalamus-pituitary-adrenal axis in patients.
AB - Liposteroid, a lipid emulsion containing dexamethasone, was developed in Japan. This drug is effective against rheumatoid arthritis, and has fewer side effects than dexamethasone. Moreover, at high dosage, liposteroid has been effectively used for the treatment of macrophage activation syndrome, because the lipid emulsions are easily taken up by phagocytes, and are retained in macrophages. Its anti-inflammatory effect was found to be 2-5 times higher than that of dexamethasone in arthritis and granuloma rat models. Japanese researchers have reported the clinical efficacy and utility of liposteroid in the treatment of diseases with macrophage activation. These include hemophagocytic lymphohistiocytosis, graft-versus-host disease, and pulmonary hemosiderosis. Here, we describe the clinical effects of liposteroid on macrophage activation syndrome and the hypothalamus-pituitary-adrenal axis in patients.
UR - http://www.scopus.com/inward/record.url?scp=84975091299&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84975091299&partnerID=8YFLogxK
U2 - 10.2177/jsci.39.190
DO - 10.2177/jsci.39.190
M3 - Review article
C2 - 27320934
AN - SCOPUS:84975091299
SN - 0911-4300
VL - 39
SP - 190
EP - 196
JO - Immunological Medicine
JF - Immunological Medicine
IS - 3
ER -